STAT

AMA urges Congress not to loosen restrictions on privacy for patients with addiction history

Pitting itself against mental health and hospital groups, the AMA is urging Congress not to allow doctors to more freely share information about a patient’s history of drug use.
Rep. Greg Walden (R-OR), left, and Rep. Frank Pallone (D-NJ), chairman and ranking member of the House Energy and Commerce Committee.

WASHINGTON — The American Medical Association is opposing a change to patient privacy laws that would allow doctors to more freely share information about a patient’s history of substance use, a proposal that has divided the health care community and highlighted some of the challenges of addressing the opioid epidemic.

In a letter to lawmakers obtained by STAT, the AMA said it believed there was a “fundamental misunderstanding” among groups working to incorporate the proposal into a . Relaxing restrictions on

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related